Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. According to TipRanks, Abrahams has an average return of 14.3% and a 56.11% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GH Research with a $43.50 average price target, a 41.97% upside from current levels. In a report released on August 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $40.00 price target.
Based on GH Research’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $18.97 million. In comparison, last year the company had a GAAP net loss of $10.81 million
